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• Observed anti-HAV antibody persistence
- in adults
- in children
• Model-based predictions
- (log)linear extrapolation
- linear mixed model
• From antibody persistence to persistence of 
protection
• Unsolved issues
Antibody persistence
• Anti-HAV persistence > cut-off level
• Different cut-off levels (10, 15, 20, 33 IU/L)
• Many years after completion of vaccination 
schedule
• very few subjects lose their antibodies
- children: up to 11 years
- adults: up to 15 years, and still ongoing (Y16-Y20)
• also in unselected populations (Rendi-Wagner et al.)
- >1000 fully vaccinated travellers
- blood sample +10 years later
- 98% still had anti-HAV >10 IU/L
Bovier 2002; Bovier (CISTM) 2005; Chan 1999; Dagan 2005; Diaz-Mitoma 2008; Fan 1998; 
Hammitt 2008; Maiwald 1997; Mayorga (ICAAC) 2003; Rendi-Wagner 2006; Totos 1997; Van 
Herck 2000; Van Herck 2001; Wang 2007; Wiedermann 1997; Wiedermann 1998; Wiens 1996
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AB persistence: hepatitis A 
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Model-based predictions
• Log-linear extrapolation method (average 
persistence)
• children: 14-25 years
• adults: 20-25 years (and beyond)
Bovier 2002; Fan 1998; Chan 1999; Maiwald 1997; Mayorga (ICAAC) 2003; 
Rendi-Wagner, Vaccine 2006; Totos 1997; Van Herck 2000; Van Herck 2001; Wang 2007 
Wiedermann 1997; Wiedermann 1998; Wiens 1996
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STEP 1: 
Modeling the change in antibody level in the estimation period
9Results
• Input data
• antibody level before second vaccine dose
• body mass index (BMI)
• Model fits the data well
• at population level
• at individual level
Long-Term Predictions
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STEP 2: 
Long term prediction
First Step: 
Validation of the model
6 years
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New observation 
(e.g.. year 7)
Prediction based 
on the first 6 years
Correlation between the predicted value at 7 years (based on 6 
years data) and the observed value.
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HAV123 (0-6): correlation
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HAV112 (0-12): correlation
All subjects:
r = 0.81
All but 3 seronegative 
subjects: r = 0.97
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Results
• Input data
• antibody level before second vaccine dose
• body mass index (BMI)
• Model fits the data well
• at population level
• at individual level
• High correlation with observations
• at population level
• at individual level
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2004: Model validation
• Using data up to year 6 (like in 2000)
- Different models
• Model 2000 (fractional polynomial with covariates)
• Model 2000 without covariates
• Linear trend with changepoint (like Bovier et al.)
- Predicting data year 7-10
• Results:
- excellent correlation (~0.90)
- slightly ↓
 
with time
Mean Structure (1): linear model 
with a change point
ijjiiij tbbY εββ ++++= )()( 1100 ijjiiij tbbY εαβαβ ++++++= )()( 111000
T
For tj < T: For tj >= T:
•We allow for a change in linear trend.
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Evolution of the mean
Second Step: 
Long-Term Predictions
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Hepatitis A: Linear mixed model 
Long-term estimates
• Individual predictions after 25 years (2000)
• anti-HAV before 2nd dose % neg. at Y25
• < 20 IU/L < 12 %
• 20-100 IU/L < 8 %
• 100-1000 IU/L < 2 %
• > 1000 IU/L < 1 %
• overall < 5 %
• Confirmed in 2004 (including Y6-Y10 data)
• consistent results with 3 different models
• Similar results with other vaccines
Bovier 2002; Bovier (CISTM) 2005; Pigeon 1999; Van Herck (ISVHLD) 2000, 2004
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Long-lasting protection
• Minimal protective level?
- not clearly defined
• Studies in chimpanzees with passive immunisation
- 10 IU/L: prevent viral shedding (but not infection)
• Vaccine trials: different (in-house) ELISA tests
- 10, 15, 20, 33 IU/L?
- comparability of results?
- Defining “protection”
- Merriam-Webster: “the state of being protected”
» 1 a : to cover or shield from exposure, injury, damage, 
or destruction
- Shielded from exposure?
- Shielded from “injury”?
Purcell, Vaccine 1992
Long-lasting protection
• Beyond persistence of antibodies
- Direct evidence
• Chimpanzees
- Challenged with HAV after vaccination
» Protected, even without anti-HAV antibodies
» Antibodies are not an absolute requirement for 
protective immunity
• Humans
- In vitro tests for cellular-mediated immunity (EliSpot)
» memory B-cells producing IgG anti-HAV 2-3 years post- 
vaccination
» T-cell immune memory: up to 6 years post-vaccination
Chen 1996; Lemon 1993; Leroux-Roels 2000; Purcell 1992
Indirect evidence: booster study
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• 12 years since Havrix 720 
(0-1-6)
• Cohort (N=150) followed for 
10 years
• Booster study: n=31
• Booster: Havrix 720
• Anamnestic response
- titre at least x2 
(or x4 if <100 IU/L at day 0)
• Day 0: 100% seropositive
• Fast, strong response within 
2 weeks
Van Herck 2004
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Unsolved issues (1)
• Observed anti-HAV persistence >15 years
• follow-up Y16-Y20 started 11/2008
• Validation of model-based predictions
• using Y11-Y15 follow-up data
• like before OR restart model fitting from scratch?
• Mathematical modelling (Fraser 2007 – HPV)
- modified power-law model
• estimating the proportion of memory cells induced
• applicable to other vaccines / infectious diseases?
• similar fit as statistical modelling?
Unsolved issues (2)
• Extrapolation to other populations
• other hepatitis A vaccines
• vaccinated children and adolescents
• vaccinated infants (effect of MATABs?)
• Duration of protection
• boostability in absence of anti-HAV
- pre-booster cellular-mediated immunity
- immune response to booster dose
» humoral
» cellular
• after single dose
After single dose: 
how long protected?
• Insufficient data, BUT good indications
- Delayed second dose (up to 5-8 years)
• Excellent anamnestic response to second dose
- Not affected by the delay
- Even after losing detectable antibodies
- Single dose of live vaccine
• Long-term persistence of antibodies and long-term effectiveness
• CAVE:
- on the long run?
- if vaccinated at young age?
- in conditions of low endemicity?
• no natural boosters
Beck 2003; Iwarson 2002; Iwarson 2004; Landry 2000; Orr 2006; 
Wang 2007; Williams 2003; Zhuang 2005
Hepatitis A 
Delayed second dose
Number 
(n)
Time of 
delay
(month)
GMT 
before
(IU/L)
GMT after
(IU/L)
Ref.
124 24–66 116 3342 Landry 2000
25 48–72° 32 2993 Iwarson 2002
156 20-31 66 1544 Williams 2003
97 18-54* 39-50 2385 Beck 2003
°JTM 2004: up to 8 years
*CISTM_2007 poster: 8-11 years
